Aplagon Doses First Patient in P-IIa (HEALING) Trial of APAC for Peripheral Arterial Occlusive Disease/Chronic Limb Threatening Ischemia

Why It Matters

If successful, APAC could fill a major unmet need in treating chronic limb‑threatening ischemia, a condition with limited options and high amputation risk. Positive data would also support broader vascular indications, expanding Aplagon’s market reach.

Key Takeaways

• First patient dosed in Phase 2a APAC trial.
• Trial enrolls ~42 CLTI patients across four cohorts.
• Evaluates safety, efficacy, and thrombo‑inflammatory biomarkers.
• PET imaging with 89Zr‑APAC slated for H1 2026.
• EU Phase 2 AVF trial planned after successful Phase 1.

Pulse Analysis

Chronic limb‑threatening ischemia (CLTI) represents one of the most severe manifestations of peripheral arterial disease, affecting millions worldwide and driving high rates of amputation and mortality. Current therapeutic armamentarium is limited to revascularization procedures and symptomatic care, leaving a sizable gap for disease‑modifying agents. APAC, Aplagon’s intravenously administered biologic, targets the intersection of thrombosis and inflammation, a mechanistic niche that could arrest disease progression and improve limb salvage outcomes. By addressing the underlying thrombo‑inflammatory cascade, APAC aims to differentiate itself from conventional antiplatelet or vasodilator therapies.

The Phase 2a HEALING trial’s design reflects a data‑rich approach, enrolling roughly 42 patients across four distinct cohorts to capture dose‑response signals and biomarker dynamics. Incorporating a 89Zr‑labeled APAC PET imaging sub‑study provides a novel pharmacodynamic readout, enabling visualization of drug distribution and target engagement in real time. Such imaging biomarkers can accelerate regulatory discussions by offering objective evidence of mechanism of action, potentially shortening the path to pivotal trials. Compared with other pipeline candidates that focus solely on angiogenesis, APAC’s dual anti‑thrombotic and anti‑inflammatory profile may yield superior efficacy in the high‑risk CLTI population.

Beyond CLTI, Aplagon’s pipeline includes a planned Phase 2 trial for arteriovenous fistula (AVF) maturation failure, leveraging the same mechanistic rationale to improve dialysis access outcomes. Success in both indications would position APAC as a versatile vascular therapeutic, opening sizable markets in both peripheral artery disease and renal replacement therapy. Investors are likely to watch the upcoming safety and efficacy readouts closely, as positive data could catalyze partnerships, broaden the company’s valuation, and signal a new class of vascular biologics poised to address unmet clinical needs.